Pharma companies directory 2026

    Pharmaceutical Companies in Libya

    Libya still buys most of its medicines as finished imports paid from oil revenue, yet authority over those purchases is split, plants have stood idle for years, and a large cash trade sits beside the official tender.

    In Tripoli the Medical Supply Organization remains the principal state importer and warehouse, while Benghazi-area facilities often buy through a separate eastern apparatus, so the same molecule can have two public prices and two delivery calendars. Azawia, Rabta and the General Company for Pharmaceutical Industries are the names ministries use when they talk about restarting local formulation; output is still thin next to Eva, Hikma, Julphar and Pharco shipments that fill both hospital crates and private pharmacies. The Food and Drug Control Center and the Ministry of Health issue papers, but enforcement is uneven and humanitarian consignments continue to plug gaps. Treat the roster as a field map of counterparties, not as proof that any single buyer controls the country.

    Updated September 2026 · Libyan Ministry of Health and Food and Drug Control Center — public supply policy and medicine control as of September 2026 · 18 named accounts

    Request a proposal for LibyaBrowse the 18 companies

    MSO

    Tripoli-based state importer and warehouse for most western public volume

    ~15 yrs

    Approximate idle stretch for Rabta-area formulation, per 2025 ministry remarks on restart talks

    2

    Public buying poles that field teams must treat separately: Tripoli and Benghazi

    Cash

    Default payment mode in private pharmacies when a tender delivery fails or never starts

    Named accounts

    Top pharmaceutical companies in Libya

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Libyan Ministry of Health and Food and Drug Control Center — public supply policy and medicine control (as of 2026-09-04).
    #CompanyHQ
    01Medical Supply Organization (MSO)Tripoli
    02General Company for Pharmaceutical Industries and Medical SuppliesTripoli
    03Azawia Pharmaceutical FactoryZawiya
    04Rabta Pharmaceutical FactoryTripoli
    05AlahliaTripoli
    06HikmaAmman
    07Eva PharmaCairo
    08Julphar (Gulf Pharmaceutical Industries)Ras Al Khaimah
    09PharcoAlexandria
    10EIPICOCairo
    11Amoun PharmaceuticalCairo
    12Dar Al DawaAmman
    13Tabuk PharmaceuticalsTabuk
    14SanofiParis
    15Food and Drug Control CenterTripoli
    16Ministry of Health (Government of National Unity)Tripoli
    17Eastern public medical-supply apparatus (Benghazi)Benghazi
    18UNICEF Libya supply lineTripoli

    Primary research

    These are the pharmaceutical companies accounts we study in Libya

    Need account-level or SKU-level data for a brand in Libya? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Libya?

    Primary research, market access & HEOR. Proposals within 48 hours.

    BioNixus research services

    How the market is structured

    Tenders in the west, cash shelves in the east, and a thin industrial base

    On paper a medicine needs a Food and Drug Control Center release and a Ministry of Health authorisation; in practice a shipment also needs a buyer who can open a letter of credit and a warehouse that will not lose the cold chain. The Medical Supply Organization in Tripoli is supposed to be that buyer for the west: it runs tenders, has been told since 2023 to pay through LCs and to deal only with official manufacturers, and in 2026 began piloting a digital supply platform. Benghazi hospitals and stores often sit outside that circuit, awarding their own lots or taking whatever a regional supplier will land at the eastern ports. Private pharmacies in both cities restock from importers such as Alahlia and from the same Egyptian, Jordanian and Gulf houses that bid the public tenders — Eva, Hikma, Julphar, Pharco, EIPICO, Amoun, Dar Al Dawa, Tabuk — so a brand that loses an MSO lot can still sell for cash on Omar al-Mukhtar Street. Local plants are a political project more than a present-day supply source: Rabta restart talks with Italian partners, a General Company board that met in 2025–2026, and the older Azawia site are real names, but they do not yet replace containers. UNICEF and WHO consignments move through a third gate and should be modelled as a competing or complementary channel, not as a company on the retail audit.

    Local

    A handful of plants and a state industrial company whose political importance exceeds their present output; restart talk is real, reliable pack flow is not.

    • General Company for Pharmaceutical Industries and Medical Supplies
    • Azawia Pharmaceutical Factory
    • Rabta Pharmaceutical Factory

    Multinational

    A thin innovator presence, Sanofi the name most pharmacists still recognise, usually working through an agent and a tender rather than a full Libyan affiliate.

    • Sanofi

    Regional

    Egyptian, Jordanian and Gulf manufacturers that actually fill crates: Eva, Hikma, Julphar, Pharco, EIPICO, Amoun, Dar Al Dawa and Tabuk.

    • Hikma
    • Eva Pharma
    • Julphar (Gulf Pharmaceutical Industries)
    • Pharco
    • EIPICO
    • Amoun Pharmaceutical
    • Dar Al Dawa
    • Tabuk Pharmaceuticals

    Distributors & importers

    MSO in Tripoli, a separate eastern buying pole in Benghazi, private houses such as Alahlia, the Food and Drug Control Center, and a humanitarian operator that moves essential packs outside the commercial tender.

    • Medical Supply Organization (MSO)
    • Alahlia
    • Food and Drug Control Center
    • Ministry of Health (Government of National Unity)
    • Eastern public medical-supply apparatus (Benghazi)
    • UNICEF Libya supply line

    What is moving

    What is moving the pharmaceutical market in Libya

    Split public buying

    A molecule awarded in Tripoli can be re-awarded, ignored or substituted in Benghazi. Any volume model that assumes one national tender will mis-state both risk and opportunity.

    Letter-of-credit discipline at MSO

    Since 2023 the Tripoli government has told MSO to pay through LCs and to deal with official manufacturers, which favours houses that can ship from a named plant and wait on bank paper.

    Cash pharmacies as the backup channel

    When a tender delivery slips, patients buy the same molecule from a private pharmacy that restocked through Alahlia or an Egyptian agent. Retail audits therefore catch demand that hospital records miss.

    Industrial restart as a long project

    Rabta and Azawia will matter if lines actually run; until then they are a political story that should not be entered as domestic share. Humanitarian consignments will keep filling the gap in the meantime.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Libya

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Libya:
    • Tripoli MSO award files placed next to dock-receipt interviews at western hospitals, to see which winning SKUs actually arrive and which are substituted from private stock.
    • Benghazi hospital and warehouse conversations that treat eastern buying as its own circuit, recording molecules that never appear on the Tripoli list.
    • Cash-pharmacy shelf walks on main retail streets in Tripoli and Benghazi, tagging Egyptian, Jordanian and Gulf origin and whether an FDCC release mark is present.
    • Site notes from visits or call-downs on Azawia and Rabta: which lines are rust, which are being re-tooled, and what a client should not assume about “local production” in a 2026 forecast.

    Questions

    Frequently Asked Questions

    Is there a single Libyan public buyer for medicines?

    No. MSO is the western state importer, and it is the right first call for a Tripoli tender. Benghazi-area facilities often buy on a different paper trail. Model two public channels plus a cash retail channel.

    Do Libyan factories supply the market today?

    Only in a limited way. Azawia and the General Company are real names, and Rabta restart talks were public in 2025, but most packs on hospital docks and pharmacy shelves are still imported finished goods.

    Which foreign manufacturers show up most often?

    Egyptian and Jordanian houses — Eva, Pharco, EIPICO, Amoun, Hikma, Dar Al Dawa — plus Julphar and Tabuk from the Gulf. Sanofi is the innovator pharmacists still name without prompting.

    Where does humanitarian supply sit in a commercial plan?

    UNICEF and WHO consignments can cover essential lines in a catchment for months, which suppresses both tender demand and pharmacy restocking. They are a channel to map, not a competitor to “beat” in a detailing sense.

    What does BioNixus actually do on a Libyan pharmaceutical brief?

    Parallel reconstruction of Tripoli MSO lots and Benghazi-area awards; cash-pharmacy stock walks in both cities; and interviews that separate legal FDCC-released goods from informal stock.

    Can the order of names in this Libyan roster be read as a size ranking?

    Nobody should read the order of rows as a statement of who is larger. The roster is a counterpart list for a split market where audited share figures barely exist.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Libya. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Libyan Ministry of Health and Food and Drug Control Center — public supply policy and medicine control, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Libya, not size.

    • Libya Herald reporting on MSO tender and LC reforms (2023), Rabta restart talks (2025) and the MSO digital supply-platform pilot (2026)
    • Food and Drug Control Center institutional site (fdcc.ly) on the centre’s quality-control mandate
    • Ministry of Health (moh.gov.ly) notices on industrial-restart meetings of the General Company for Pharmaceutical Industries
    • BioNixus Libya tender, pharmacy and hospital fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Libya?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Libya?

    Primary research, market access & HEOR. Proposals within 48 hours.